$7.42 0.00 (%) Keryx Biopharmaceuticals - NASDAQ

Jul. 25, 2016 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics

    GuruFocus | Jul. 12, 2016 | 10:53AM EST
  2. Klarman Gives Insight on Keryx Biopharmaceuticals Investment

    GuruFocus | Jan. 26, 2016 | 15:04PM EST
  3. Seth Klarman Blames Market, Investments for Rare Down Year

    GuruFocus | Jan. 25, 2016 | 17:04PM EST
  4. Mid-Day Market Update: Cintas Gains On Earnings Beat; NetApp Shares Slide

    Benzinga | Dec. 22, 2015 | 12:20PM EST
  5. David Abrams Buys Stake in Heavy Equipment Company

    GuruFocus | Dec. 15, 2015 | 18:19PM EST
  6. Why Seth Klarman Keeps Buying Keryx Biopharma

    GuruFocus | Nov. 3, 2015 | 12:36PM EST
  7. Seth Klarman Raises Position in Keryx Biopharmaceuticals

    GuruFocus | Oct. 21, 2015 | 17:24PM EST
  8. Mid-Day Market Update: Weight Watchers Jumps On Oprah Stake; Great Lakes Dredge & Dock Shares Drop

    Benzinga | Oct. 19, 2015 | 12:34PM EST
  9. Mid-Afternoon Market Update: Dow Jumps 175 Points; Garmin Shares Slip On Weak Preliminary Q3 Results

    Benzinga | Oct. 15, 2015 | 15:28PM EST
  10. Mid-Day Market Update: Crude Oil Down 2%; Five Prime Therapeutics Shares Spike Higher

    Benzinga | Oct. 15, 2015 | 12:25PM EST
  11. Morning Market Gainers

    Benzinga | Oct. 15, 2015 | 09:48AM EST
  12. Seth Klarman Buys Pharmaceutical Company's Shares to Fund International Drug Launch

    GuruFocus | Oct. 12, 2015 | 17:36PM EST
  13. Morning Market Gainers

    Benzinga | Oct. 5, 2015 | 09:47AM EST
  14. Keryx Pharma: Citigroup Says EU Approval Was As Expected And Doesn't Change The Banks' Sell Thesis, Maintains PT $1.50

    Benzinga | Sep. 24, 2015 | 12:27PM EST
  15. Mid-Morning Market Update: Markets Tumble; Accenture Tops Q4 Estimates

    Benzinga | Sep. 24, 2015 | 10:33AM EST
  16. Morning Market Gainers

    Benzinga | Sep. 24, 2015 | 09:41AM EST
  17. Stock Futures Down, Volatile; Accenture, Caterpillar Slide

    IBD | Sep. 24, 2015 | 09:05AM EST
  18. Benzinga's Top #PreMarket Gainers

    Benzinga | Sep. 24, 2015 | 08:08AM EST
  19. Mid-Day Market Update: Joy Global Drops On Earnings Miss; Methode Electronics Shares Spike Higher

    Benzinga | Sep. 3, 2015 | 13:01PM EST
  20. Mid-Morning Market Update: Markets Gain; Campbell Soup Earnings Top Estimates

    Benzinga | Sep. 3, 2015 | 10:29AM EST
  21. Mid-Day Market Update: Tuesday's Top Shorted Stocks

    Benzinga | Aug. 18, 2015 | 14:28PM EST
  22. Is Seth Klarman right about Keryx Inc.?

    GuruFocus | Jun. 25, 2015 | 11:49AM EST
  23. Morning Market Losers

    Benzinga | May. 4, 2015 | 09:59AM EST
  24. UPDATE: Keryx Biopharmaceuticals Posts Q4 Loss

    Benzinga | Feb. 27, 2015 | 08:22AM EST
  25. Earnings Scheduled For February 27, 2015

    Benzinga | Feb. 27, 2015 | 05:14AM EST
  26. Stocks Hitting 52-Week Lows

    Benzinga | Feb. 9, 2015 | 10:21AM EST
  27. 2015 Must-Buys In Biotech Sector

    GuruFocus | Feb. 2, 2015 | 15:26PM EST
  28. 4 More Biotech Secondaries Traders Are Watching

    Benzinga | Jan. 21, 2015 | 13:38PM EST
  29. Morning Market Losers

    Benzinga | Jan. 21, 2015 | 09:55AM EST
  30. Wednesday Morning Movers: Netflix Flying High

    Benzinga | Jan. 21, 2015 | 08:55AM EST
  31. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2

    Benzinga | Jan. 12, 2015 | 11:03AM EST
  32. Seth Klarman Keeps Buying LNG, KERX, PBF And Keeps Selling THRX

    GuruFocus | Dec. 5, 2014 | 10:47AM EST
  33. Keryx Reports Issuance of New US Patent for Auryxia(TM) Covering Orally Administrable

    Benzinga | Dec. 4, 2014 | 07:33AM EST
  34. Keryx Offers Phase 2 Trial Results for Auryxia in NDD-CKD Patients

    Benzinga | Dec. 2, 2014 | 07:33AM EST
  35. Auryxia Phase 2 Data Published In The American Journal Of Kidney Disease

    Benzinga | Dec. 2, 2014 | 07:30AM EST
  36. Mid-Day Market Update: SunEdison, TerraForm Jump On First Wind Acquisition; TJX Shares Drop

    Benzinga | Nov. 18, 2014 | 13:17PM EST
  37. Events for the Week of Nov. 17-21, 2014

    Benzinga | Nov. 17, 2014 | 13:13PM EST
  38. Baupost's Seth Klarman Buys Cheniere Energy, Ocwen Financial, Antero Resources, Sells Boyd ...

    GuruFocus | Nov. 14, 2014 | 18:08PM EST
  39. Infoblox Inc Gains On Upbeat Results; The Gap Inc. Shares Decline

    Benzinga | Sep. 5, 2014 | 12:36PM EST
  40. Seth Klarman's The Baupost Group Buys eBay, SunEdison Semiconductor, Keryx Biopharmaceuticals, ...

    GuruFocus | Aug. 14, 2014 | 19:02PM EST
  41. H.C. Wainwright & Co. Believes Keryx Biopharmaceuticals Remains Undervalued

    Benzinga | Aug. 8, 2014 | 09:24AM EST
  42. UPDATE: Keryx Announces Zerenex LT Phase 3 Results Shows 'Highly Statistically Significant' Change, Met Primary Endpoint

    Benzinga | Jul. 24, 2014 | 17:04PM EST
  43. Seth Klarman Tops Guru Scoreboard for First Half 2014

    GuruFocus | Jul. 5, 2014 | 16:52PM EST
  44. Seth Klarman Is Top-Performing Guru for First Half 2014

    GuruFocus | Jul. 5, 2014 | 16:52PM EST
  45. Morning Market Movers

    Benzinga | Jun. 24, 2014 | 09:40AM EST
  46. Baupost's Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals

    GuruFocus | May. 12, 2014 | 18:43PM EST
  47. UPDATE: MLV & Co Reiterates On Keryx Biopharmaceuticals On Increased Risk

    Benzinga | May. 12, 2014 | 08:12AM EST
  48. Keryx Biopharma Reports Zerenex Phase 2 Results in Non-Dialysis Dependent Chronic Kidney Disease Selected as a Late Breaking Oral Presentation at the Upcoming National Kidney Foundation 2014 Spring Clinical Meeting

    Benzinga | Apr. 9, 2014 | 08:33AM EST
  49. Keryx Biopharmaceuticals Announces EMA Validation of Marketing Authorization Application for Zerenex

    Benzinga | Apr. 2, 2014 | 08:32AM EST
  50. Mid-Afternoon Market Update: Markets Turn Red as Dish Network Rises

    Benzinga | Mar. 26, 2014 | 15:46PM EST
Trading Center